7 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
European Research Infrastructures for Poverty Related Diseases (EURIPRED)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
HIV/AIDS, Tuberculosis (TB) and Malaria alone account for more than six million deaths worldwide every year. Despite substantial efforts made in recent years, Poverty Related Diseases are still spreading. New therapeutic interventions are therefore urgently required to combat Poverty Related Diseases. The existence of a well-developed HIV/TB/Malaria infrastructure presents a prime opportunity to a ...
Voir le projet
18
Participants partenaires
TERMINÉ
The impact of DEmographic Changes on Infectious DisEases transmission and control in middle/low income countries (DECIDE)
Date du début: 1 avr. 2012, Date de fin: 31 mars 2017,
Population structure and change and social contact patterns are major determinants of the observed epidemiology of infectious diseases, including the consequences on health. Demographic structure and the components of demographic dynamics are changing over time and substantially differ within countries and most critically between countries. However, some of the overall consequences of demographic ...
Voir le projet
4
Participants partenaires
TERMINÉ
African Vector Control: New Tools (AvecNet)
Date du début: 1 févr. 2011, Date de fin: 31 déc. 2016,
The AvecNet consortium will develop practical solutions to the current limitations of vector control strategies in Africa using a combination of translationally-aware, state of the art science and end user analysis to ensure successful development and uptake of the new and improved approaches to malaria control and elimination. Our carefully balanced, multidisciplinary team of European and Africa ...
Voir le projet
17
Participants partenaires
TERMINÉ
Dissecting the Immunological Interplay between Poverty Related Diseases and Helminth Infections: An African-European Research Initiative (IDEA)
Date du début: 1 mars 2010, Date de fin: 31 août 2015,
Worm infections are receiving increased attention due to: the wide geographic overlap in occurrence between worms and HIV, TB and malaria; the large proportion of individuals (minimal estimates around 25%) co-infected with worms and HIV/TB/ malaria; the potential risk of increasing disease burden; the very limited understanding of the impact by worm infections on HIV-, TB- and malaria-specific imm ...
Voir le projet
23
Participants partenaires
TERMINÉ
Health, environmental change and adaptive capacity: mapping, examining and anticipating future risks of water-related vector-borne diseases in eastern Africa (HEALTHY FUTURES)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,
The HEALTHY FUTURES project is motivated by concern for the health impacts of environmental changes. HEATHLY FUTURES aims to respond to this concern through construction of a disease risk mapping system for three water-related high-impact VBDs (malaria, Rift valley fever and schistosomiasis) in Africa, accounting for environmental/climatic trends and changes in socio-economic conditions to predic ...
Voir le projet
17
Participants partenaires
TERMINÉ
Genome-driven vaccine development for bacterial infections (GENDRIVAX)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,
...WTSI), academic institution working in the research areas of genetics.3. Swiss Tropical Institute (STI), a public non-commercial organisation with the mission of contributing to health development.4. Kenya Medical Research Institute (KEMRI), the national body responsible for carrying out health science research in Kenya.The four partners have existing links that form the basis for developing an ef ...
Voir le projet
4
Participants partenaires
TERMINÉ
The targeted development of a new generation Vaccine for Schistosomiasis (TheSchistoVac)
Date du début: 1 févr. 2010, Date de fin: 31 juil. 2014,
The aim of this project is to develop a new generation vaccine for schistosomiasis. The vaccine will be based on exposed proteins and/or glycans of the vulnerable skin stage schistosomula, making it safe and effective. The life stage-specific vaccine target selection strategy is based on state-of-the-art schistosomal transcriptomics and glycomics technologies and data, and unique serum and sample ...
Voir le projet